UK markets open in 37 minutes

Tarsus Pharmaceuticals, Inc. (TARS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.03+0.18 (+0.49%)
At close: 04:00PM EDT
36.04 -0.99 (-2.67%)
After hours: 06:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close36.85
Open37.00
Bid37.04 x 200
Ask37.26 x 100
Day's range36.35 - 37.85
52-week range12.57 - 40.40
Volume679,524
Avg. volume695,873
Market cap1.399B
Beta (5Y monthly)1.05
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

    IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1.30 p.m. PT / 4.30 p.m. ET on Wednesday, May 8, 2024 to report its first quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the

  • GlobeNewswire

    Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

    IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital avai

  • GlobeNewswire

    Tarsus to Participate at Upcoming Investor Conferences

    IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will participate in the following conferences: Guggenheim Healthy Altitudes Summit (Telluride, CO) Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in a fireside chat on Wednesday, March 13, 2